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Introduction
As the genes and proteins are the fundamental 
components of biological systems, they are considered as 
central focus of advances in molecular and cellular biology. 
Recent progresses in genomics and proteomics have led to 
the advent of high-throughput screening methods such as 
microchips, or “lab on a chip (LOC) structures, or micro 
total analysis system (μTAS) (Figeys and Pinto, 2000). 
Being adapted to simultaneous analysis of hundreds of 
different samples (Sato et al., 2002). each comprising 
variable parameters, the microchips has gained many 
advantages over macro-scale methods regarding efficiency 
and affordability (Kartalov et al., 2006). In the last decades 
with progressive arrival of microchip technology, a body 
of biochemical and biological experiments has been 
performed using this technology with remarkable efficacy. 
Several experiments which are commonly performed by 
these microchips are listed in Table 1. In fact by the advent 
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Abstract
 In micro-fluid systems, fluids are injected into extremely narrow polymer channels in small amounts such as 
micro-, nano-, or pico-liter scales. These channels themselves are embedded on tiny chips. Various specialized 
structures in the chips including pumps, valves, and channels allow the chips to accept different types of fluids 
to be entered the channel and along with flowing through the channels, exert their effects in the framework 
of different reactions. The chips are generally crystal, silicon, or elastomer in texture. These highly organized 
structures are equipped with discharging channels through which products as well as wastes of the reactions are 
secreted out. A particular advantage regarding the use of fluids in micro-scales over macro-scales lies in the fact 
that these fluids are much better processed in the chips when they applied as micro-scales. When the laboratory 
is miniaturized as a microchip and solutions are injected on a micro-scale, this combination makes a specialized 
construction referred to as “lab-on-chip”. Taken together, micro-fluids are among the novel technologies which 
further than declining the costs; enhancing the test repeatability, sensitivity, accuracy, and speed; are emerged 
as widespread technology in laboratory diagnosis. They can be utilized for monitoring a wide spectrum of 
biological disorders including different types of cancers. When these microchips are used for cancer monitoring, 
circulatory tumor cells play a fundamental role.  
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of micro-analyzing methods like HPLC in the past; several 
revolutionary changes in cellular and molecular biology 
which demanded high sensitive detectors; the advent of 
micro-systems and a breakthrough in micro-electronics 
industry; and finally the desire of human to apply low 
cost, portable and high-throughput systems for detection 
of different disorders resulted in the emerging of current 
high-tech microchips (Whitesides, 2006). 
These appealing micro-systems firstly described in 
1958 by Jack Kilby, an American electronic engineer, 
who in 2000 honored by Nobel Prize in physics. Primarily, 
the system had an elementary structure. Subsequently, 
more advanced micro-fluidic systems were developed in 
the form of gas chromatography in 1970. For almost 20 
years, these novelties have not attracted many scientists. 
But since 1990, a wide spectrum of distinct investigations 
has dedicated in this field of study which revolutionized 
the science, especially the medical technology. (Dingwall, 
1979; Smith, 1984; Holden, 1989; Zubritsky, 1999; 
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The chips were first made primarily by crystal and 
silicium which then replaced but other more proper 
materials such as poly dimethyl silicone (PDMS) and 
a kind of epoxy polymer called SU-8 for enhancing the 
chip efficacy (Reyes et al., 2002). Particularly, in the 
construction of a chip, the structural components are 
fixed on a specialized surface in micro-scales. The surface 
generally has crystal, ceramic, polymers like PMDS and 
SU-8, stainless steel, or Teflon, in texture. The micro-
chip materials mainly divided into 3 major categories: 
inorganic, polymer, and paper-based materials. Selecting 
the base material for a special micro-fluidic system is over-
shadowed by the base technology which the micro-chip 
is working with. Some of the most determined types of 
these associations are summarized in Table 2 (Marques 
and Fernandes, 2011). 
Since in the production of microchips the components 
in use are tiny, it obviates the need for large manufactures. 
Other considerable advantages of using the micro-fluidic 
systems are decrease in costs and energy consumption, and 
also the reduction of harmful effects on the environment 
(Nind, 1999). It should be highlighted that another benefit 
Table 1. Several Experiments and Methodologies which 
Have Been Performed in the Frame of Different Types 
of Microchips
Reference Technology
(Hamilton, 1990) Micro-chemical analyzing
(Ekins and Chu, 1991) Immunoassay
(Southern et al., 1992) Arrays of oligonucleotides
(Fahy, 1993) Molecular nanotechnology
(Maier et al., 1994)
Oligonucleotide 
hybridization
(Jacobson and Ramsey, 
1995)
Electrophoresis
(Tracey et al., 1995) Cell analysis; Deformability
(Kricka, 1998)
Clinical automation & 
robotics
(Cheng et al., 1996b) Probe ligation; LCR
(Parinov et al., 1996) DNA sequencing
(Jacobson and Ramsey, 
1996)
Probe ligation; Restriction 
fragment analysis
(Cheng et al., 1996a) Molecular diagnostics
(Li and Harrison, 1997) Cell analysis; Isolation
(Xue et al., 1997) Mass spectrometry
(Guschin et al., 1997) DNA synthesis
(Hadd et al., 1997) Enzyme assay
(Barnaby, 1997)
detection of biological 
warfare agents
(Cheng et al., 1998)
Nucleic acid amplification; 
Multiplex PCR 
(Cheng et al., 1998)
Nucleic acid amplification; 
DOP-PCR
(Ibrahim et al., 1998) Real-time PCR
(Schrum et al., 1999) Flow cytometry
(Dolnik et al., 2000) Capillary electrophoresis
(Schmalzing et al., 2000) SNP detection
(Lockhart and Winzeler, 
2000)
Gene expression studies & 
microarray
(Tudos et al., 2001) point of care testing
(Verpoorte, 2002) forensic analysis
(Kricka and Wilding, 2003) PCR
(Garcia-Egido et al., 2003) combinatorial chemistry
(Kartalov and Quake, 2004) microELISA
(de Boer et al., 2005)
Capillary liquid 
chromatography
(Craighead, 2006) single molecule analysis
(Dittrich and Manz, 2006) drug discovery
(Kim et al., 2007)
culture of adherent 
mammalian cells
(Nge et al., 2013) Proteomics
(Martinez et al., 2008)
Laser induced fluorescence 
(LIF)
(van Noort et al., 2009) Stem cell research
(Price et al., 2009) Nucleic acid assays
(Granieri et al., 2010)
protein and cell-based drug 
screening
(Agresti et al., 2010) biomolecule production
(He and Herr, 2010) Immunoblotting
Reference Technology
(Wang and Bodovitz, 2010) Metabolomics
(Koirala et al., 2011) DNA/microRNA profiling
(Kumar et al., 2011)
Hybrid Opto-Electric Ma-
nipulation
(Jokerst et al., 2012) Environmental analysis
(Nge et al., 2013) Space exploration
(Sheng et al., 2012) Electrochemical Detection
(Olsen et al., 2013) Cell migration analysis
(Jarvas and Guttman, 2013) Cell sorting
(Luongo et al., 2013)
Electrical impedance spec-
troscopy
(Masrie et al., 2014)
Bio-particle concentration 
assay
(Ohnishi et al., 2014)
Nucleic acid sandwich 
hybridization 
(De et al., 2014) Epigenetic analysis
(Zhou et al., 2014) Monitoring cell secretion
(Wu et al., 2015) Somatic cell reprogramming
(Yoon et al., 2015) Methylation analysis
(Ali et al., 2015) PCR-RFLP
(Pandya et al., 2015)
Electro-Mechanical pheno-
typing
(Rackus et al., 2015)
Electrochemical immunoas-
say
(Kao et al., 2015) FISH
(Hsu et al., 2015) MeDIP
(Guan et al., 2016)
Electrochemiluminescence 
detection
(Jastrzebska et al., 2016)
Heart-on-a-chip (stem cell 
biology)
Table 1 (Continued). Several Experiments and 
Methodologies which Have Been Performed in the 
Frame of Different Types of Microchips
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Table 2. A Summarized Review of Process Variables which Can Affect the Selection of Base Material for Microchip 
Production
Reference Characteristics Types of materials in use
(Iliescu et al., 2012)
Is categorized in inorganic materials. It is the first material used in 
microchip synthesis. Having highly elastic features, it used commonly 
to construct the structural components of microchips such as pumps 
and valves. It is compatible with high temperature and pressure but 
incompatible with the strong basic solutions. It has previously used in 
microchips for PCR purposes. 
 Silicone
(Shadpour et al., 2006)
It is the second most common material used in microchips which is 
transparent and inorganic. It is compatible with biological liquids and still 
widely used in microchip structure. It generally has intensive resistance 
against chemical substances while is incompatible with strong basic 
solutions. It is also impermeable to gases. 
Glass
(Wilson and Kolbinson, 
1983)
It is categorized as inorganic and is basically has laminar structure which 
is ammonium oxide in texture. It is highly temperature and pressure 
resistant. The main disadvantage is high prices and shrinking after 
intensification. It predominantly used in ELISA microchips and proteomic 
studies. 
Ceramic
(Chen et al., 2004)
It has inorganic and compatible with high temperature and pressure while 
sensitive to corrosive solutions. It destroyed by these substances unless it 
protected by special metallic covers.  
Stainless steel
(Pandian et al., 2010)
It is inorganic and very resistant to different solvents. This approach is a 
relatively unexploited and much about its characteristics are remained to 
be fully described.   
Teflon
(Chen et al., 1999)
It is organic and a member of polymer substances. Thermoplastics are also 
cost  effective, they are rapidly formed but are incompatible with organic 
solvents, temperature, and high pressure.  
Thermoplastics
(Klasner et al., 2009)
PDMS is categorized in polymeric elastomers. Having low elasticity 
modulus, facility in synthesis, low prices, as well as permeability to gases, 
PMDS is extensively used as base material in various kinds of chips.   
Polydimethylsiloxane
(PDMS)
(Kovarik et al., 2013)
TPE is in the polymer group. It is a hydrophobic substance, therefore is 
able to facilitate the flow of liquids through the super narrow channels of 
microchips. 
Thermoset polyester
(TPE)
(Kovarik et al., 2013)
Basically is vinyl benzene in texture. As it has a high biocompatibility, it is 
an ideal polymer for cell culture purposes. Polystyrene
(Kovarik et al., 2013)
It is a type of polymer consisting two main subunit as bisphenol A and 
phosgene. Having a high resistance against temperature it has used in the 
chips working as DNA thermal cyclers.  
Polycarbonate
(Fiorini et al., 2003)
PMMA is a derivative of polymers which has a high biocompatibility. It 
is impermeable to different gases and very resistant to high temperatures. 
Plexiglas and Lucite are among the commercial products of these 
substances which are prevalently applied in making microchips
Poly(methyl meth-
acrylate)
(Wu et al., 2012)
Polyurethane is a polymer with an acceptable biocompatibility. It is 
resistant to basic and acidic solutions. Polyurethane
(Ren et al., 2011)
Fluoropolymers have derivatives such as fluorinated ethylene-propylene 
(FEP) and perfluoroalkoxy polymer (PFA). They are highly resistant to 
corrosive solutions and they have a moderate plasticity capacity. 
Fluoropolymers
(Gustafsson et al., 2008)
COC is completely transparent and has a high plasticity capacity. It is 
hydrophobic and is widely used in the microchips for protein purification 
purposes. 
Cyclic-olefin copoly-
mer
(Luecha et al., 2011)
Zein is a type of polymer derived from corn protein. It is currently 
considered as a proper replacement for petroleum-based polymers.  Zein
(Castano-Alvarez et al., 
2009)
SU – 8 is a type of polymer with a high plasticity capacity which is 
transparent to visible light but in the ultraviolet spectrum has orange-
brown color. It is an epoxy-based photoresist which is able to transform to 
a multi-layer structure. 
SU – 8
(Kumar et al., 2015)
It is cellulose in structure, cheap and accessible and can simply be 
excreted. Due to its porous structure, it provides filtration and separation 
of materials. It has also a high level of bio-compatibility.
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of micro-fluidic systems is that they are able to provide 
a system that allows the reactions to be performed with 
a greater efficiency. According to the diffusion rules of 
liquids, where the distances between the materials in an 
especial reaction become closer, in the other hand the 
amount of the components decrease into nano- or femto-
liter scales, the interaction of these components reaches 
to their maximum levels which can eventually allow the 
reaction to be performed faster and more comprehensive. 
Furthermore, as the scales are decreased, intra-molecular 
and tensile forces lose their interaction, while the viscosity 
and inter-molecular forces become predominant (Marques 
and Fernandes, 2011). Performing the various reactions 
such as molecular labeling, refinement, isolation and 
monitoring of the products at the same time are among 
the unique characteristics of micro-fluidic systems 
which allow the systems to accomplish a wide spectrum 
of experiments with the maximum levels of accuracy 
and efficacy (Cibilic, 2000). Undoubtedly, working 
in the frame of these micro-scales also facilitates the 
transportation of experimental milieu which is a great 
advantage over the large scale environments (Nge et al., 
2013). In order to produce the micro-fluidic tools in the 
large commercial amounts they must be primarily tested in 
real scales. It means that their functions must be compared 
with the results obtained from macro-labs hence the results 
can be precisely attributed to the microchip. During these 
analyses, variety of aspects including volumes and types 
of materials, characteristics of devices, final products of 
reactions and also wastes and pitfalls have to be studied 
(Nge et al., 2013). Nowadays, commercial micro-fluid 
systems are presented by different companies including 
Abbot, Agilent, Micralyne, Dolomite, Micrux, and Caliper 
(Whitesides, 2006).
Nowadays, advanced micro-electromechanical 
systems (MEMS) are incorporated into biologic detectors 
and play especial roles as sensors. These systems 
encompass electrical and mechanical components 
(Chuang et al., 2010). In fact, micro-analytic systems 
which are working in Lab-on-chips structures are chemical 
analogous of MEMS which are applied as proper synthetic 
structures for analysis of multiple processes on a micro-
scale laboratory. For example, a classical Lab-on-chip 
structure may selectively separate a highly complex 
solution to its constituents and identify these different 
compounds with high accuracy. To analyze the above 
reactions, designing a highly advanced micro-detector 
in the structure of chips is inevitable (Nge et al., 2013). 
The micro-fluidic systems include ultrafine synthetic 
structures with a maximum capacity of several hundred 
femto-liters (fl) to several hundred nano-liters (nl) of 
samples tested and their metabolites (Guzman and Phillips, 
2011). In the other word, these micro-systems measure 
only 1.5 cm to 1.5 cm and a thickness of approximately 
a few millimeters (Minhas, 2015). The overall structure 
consist a central core with multiple components including 
several micro-channels, tanks, valves, and chambers 
[Figure1]. Generally, tanks and micro-fluidic channels 
have laminar flow, a low final volume, and a high surface 
to volume ratio. For example, a separator channel in an 
electrophoresis microchip has a dimension of just 50mm 
in wide, 15mm in length and 5cm in height which has a 
capacity of 5.37 nano-liters. Other components which 
optimize the performance of chips are finally added to 
the core. These components generally include sensors, 
membranes, columns, monoliths and pneumatic controls 
(Nge et al., 2013).
As mentioned above, it has been attempted to describe 
some structural details, components and performance of 
the microchips. However, the main purpose of this review 
is to discuss the importance of chips in the diagnosis and 
monitoring of malignancies. 
Key Points In The Production of A Microchip
For the first time photolithography technology used 
to produce microchips. In 1998, with the advent of soft 
lithography technology, micro-scale modeling became 
accessible to scientists (Whitesides et al., 2001). In a 
microchip it is demanded to substantially increase the 
surface to volume ratio. In chip manufacturing, in order 
to adjust rising levels of biological communication with 
each other, the Self-Assembled Monolayers (SAM) 
is used. SAM consists of successive layers of alkane 
thiols, which are located on thin plates of gold. Using of 
these layers is a constitutive step during the production 
of biological micro-systems (Mrksich and Whitesides, 
1996). In the microchip production several key points 
should be noted: the choice of materials used and the 
physical form of chips and components. Furthermore, the 
location of valves and channels should be determined on 
the basis of principles of engineering. In this framework, 
choosing various strategies depends on the final function 
of microchip that we expect to achieve. On the other hand, 
the injection of biological material in different places 
should be performed according to the function of the chip. 
This injection has to be done with pre determined purpose 
and fully planned. In other words, to create a pattern of 
targeted chemical and specific movement of any material 
to the designated location; design, material and internal 
surface properties of the channel should be such that any 
material would attract specifically to its target location. 
Soft lithography technology allows the certain chemical 
patterns to be designed for the chip manufacturing 
purposes. On the other hand, using a variety of SAMs, 
adhesion, humidity and other molecular properties of 
surfaces can be manipulated based on type and function 
of the chip. These properties can be changed according 
Figure1:	  A	  structural	  view	  of	  a	  diagnos6c	  chip	  (
Liu	  et	  al.,	  2004)	  
	
Figure 1. A Structural View of  Diagnostic Chip (Liu 
et al., 2004)
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to a desirable profile (Brivio et al., 2006).
Fundamental Functions in a Chip
Fundamental functions are the major operations in 
micro-fluid systems which ultimately give the chip this 
ability to conduct targeted testing and favorable analysis 
in order to provide reliable results. These functions 
include sample preparation, separation of materials, 
tracking, and transitions of fluids (Nge et al., 2013). To 
facilitate the better understanding of the content, brief 
details of the actions are shown in Table 3. In fact, the 
final purpose of Lab-on-chip systems is the integration 
of all the laboratory processes on a micro-system where 
sample preparation, biochemical reactions, separation, 
detection, and ultimately accurate data analysis can be 
done (Wu et al., 2010). Despite all the recent scientific 
developments in relation to the microchips, the inclusion 
of all laboratory steps on a single micro unit system is not 
simply possible and faced with various difficulties (Sin 
Table 3. Functions that Should be Included in a Diagnostic Microchip, as Well as Components and Common 
Techniques Used in Every Stage
Critical actions Procedures or methods Description Reference
Sample preparation
Extraction and 
purification
This is a part of sample preparation before performing the main 
test. A preferred method of choice for this purpose is Solid 
Phase Extraction (SPE). In the majority of microchips, a kind of 
SPE system called reversed-phase SPE columns is used. In this 
technology the mostly used columns are silica-based. In this case, 
the extraction is performed based on affinity with high specificity.
(Wen et al., 2008)
Pre-concentration
By this method, samples with small amounts can be used 
efficiently and the results will be more accurate. One of the most 
common technologies at this stage is Isotachophoresis (ITP). Two 
other techniques which are used here are temperature gradient 
focusing and sweeping.  
(Bercovici et al., 
2011)
On-chip labeling
The labeling is generally performed either on samples in use (Off-
chip) and also on certain parts of the microchip (On-chip). Micro-
chip labeling is accomplished with two main types: Pre-column 
and Post-column
(Sieben and 
Backhouse, 2005)
Separation methods
Chromatography This is a sensitive and reliable method. In this step the liquid chro-
matography- and HPLC- based methods are used.
(Taylor et al., 
2010)
Electrophoresis
This is an efficient liquid-based separation method. Notable 
benefits of this technique are high efficiency, high speed and 
consumption of very small amounts of sample. In some chips 
for better separation, a combination of this methods and 
chromatography is applied (electrochromatography). Other 
techniques that are used here are Isoelectric focusing and Micellar 
electrokinetic chromatography.
(Yang and 
Woolley, 2010)
Fractionation
One technique that works for separation based on this method is 
Digital isoelectric fractionation. This technique uses membranes 
with distinct specific PH dedicated to separate analytes based on 
their isoelectric points. It is largely used in the chips dedicated 
for detection of glycoprotein onco-markers in biological samples. 
Another technique in use in this step is Field-flow-fractionation. 
(Mai et al., 2012)
Detection methods
Optical detection
These types of high precision methods are divided into two sub-
groups: 1- label-based methods such as fluorescence, 2- label-
free methods such as chemiluminescence. Fluorescence methods 
compared with the second group have a higher sensitivity. 
The most common optical method which is used for detection 
purposes in microchips is Laser-induced fluorescence. In 
contrast, UV absorbance is a labeling-free method which is also 
commonly used in HPLC and electrophoresis systems.  
(Myers and Lee, 
2008)
Electrochemical 
detection
They are as sensitive as macro-scale electrochemical detectors. 
Today, Conductivity, amperometry and potentiometry are the 
most common technologies in conjunction with this method, 
used in microchips.
(Holcomb et al., 
2009)
Mass 
spectrometry 
(MS)
MS is capable to convert tiny differences into data based on 
mass differences and then record these data. Two ionization 
technologies associated with this method, which are used in a 
group of microchips include: (ESI-MS) and matrix-assisted laser 
desorption / ionization (MALDI-MS). The former is used more 
common in microchips.  
(Kleparnik, 2013)
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et al., 2011). Technologies such as Fluidic interconnects 
(Mair et al., 2006), Micro-dialysis (Nandi and Lunte, 
2009), and Droplet micro-fluidics (Seemann et al., 2012) 
are among the methods which are currently used for 
optimum integration of processes performed on a chip. 
Cancer and the Challenges Ahead
Cancer or malignancy is defined as the indiscriminate 
and uncontrolled proliferation of normal cells in the body. 
Currently, cancer is one of the most complex disorders 
that plague the human being and is one of the main causes 
of death around the world. In other words, according to 
published statistics, in developed and under-developed 
countries cancer is the second and third cause of death, 
respectively. Although in the last decades remarkable 
breakthroughs have been made, and diagnosis and 
monitoring of various malignancies are performing 
accurately, but many aspects of this challenging disorder 
remain to be fully clarified. Failure of many theories and 
techniques in screening and early diagnosis of cancer, 
lack of full understanding of the pathogenesis of cancers, 
imperfect and unreliable remedies, tolerance of tumor 
cells against current modalities, frequent relapses after 
remission phase, heterogenic chromosomal abnormalities, 
plasticity of malignant cells and finally tumor metastasis 
are among the most important challenges in dealing with 
cancer (Azad et al., 2015).
In most cases, cancer originates from one or multiple 
chromosomal abnormalities, which can lead to a clonal 
disorder, changes in gene expression profiles, cell 
cycle and apoptosis deregulation and eventually the 
cell will undergo uncontrollable proliferation. Genetic 
abnormalities which lead to malignancy primarily occur 
in key elements of intracellular signaling, proto-oncogenes 
and tumor suppressor genes. Since 2004, abundance of 
investigation efforts has been accomplished to precisely 
identify the biology of cancers, which has accelerated the 
prevention, diagnosis, and treatment strategies of these 
disorders (Alexis et al., 2008). Obviously, there is a long 
elapse between initiation of chromosomal disorders and 
cancer formation in the body. As a result, if the cancer 
would be detectable prior to complete formation of tumor 
bulk, its management would be easier and the treatment 
might be more successful (Seigneuric et al., 2010).
Certainly, in each stage of a tumor an ideal sampling 
can strongly affects the diagnosis and treatment strategies. 
Therefore, the sampling is always one of the most 
important challenges regarding the cancer diagnosis 
(Mach et al., 2013). Traditional sampling methods such 
as collecting the biopsy from suspicious tissues are quite 
invasive and painful which harm the patient’s body. 
As a result, preparing a proper and sufficient sample is 
not always easily made. Having these obstacles, it has 
been tried to make the cancer diagnosis feasible using 
body fluids especially blood, urine, and saliva which 
are more accessible with the minimum risk. One of 
these methodologies is to detect the cancer associated 
circulatory biomarkers in these fluids which can be 
considered as markers for prevention, prognosis, diagnosis 
and monitoring of cancers (Fabian et al., 2008). Bio-
molecules including DNA, mRNA, micro-RNA, proteins, 
lipids, exosomes, and the most important, circulatory 
tumor cells (CTCs) are among the most common 
biomarkers used for this purpose. According to previous 
studies, in addition to the affected tissues, tumor cells are 
also detectable in body fluids especially blood in which 
1-10 malignant cells/ml are identifiable in patients with 
solid tumors. More precisely, prior to metastatic phase, 1 
CTC per 108 mononuclear cells can be detected in blood 
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Critical actions Procedures or methods Description Reference
Fluid manipulation
Pumps
Hydraulic fluid is a vital function in microchips which accelerates 
the solution. The main types of pumps used in different microchips 
based on their functions are divided into two categories: Passive 
and Active. Sub-group Non-Mechanical Capillary belongs to the 
type of Passive. Active category has different sub-groups which 
are as follows: Electro-osmotic, Electrochemical, Pneumatic 
peristaltic, Electro-hydrodynamic, Acoustic and Magneto-
hydrodynamic. 
(Lai and Folch, 
2011)
Valves
The most common material used to produce micro-fluid valves 
is PDMS. Having the ability to control the flow rate as well as 
their especial direction, valves are playing important roles in 
microchips. Valves are divided into two categories: Passive and 
Active. Passive types include the following groups: Check valve 
(mechanical) and Capillary burst valve (non-mechanical) and 
active includes the following groups: Pneumatic (mechanical) 
and Phase-change (non-mechanical) and Magnetic (mechanical).
(Kim et al., 
2012a)
Mixing
Laminar flow of materials in small quantities together with 
super narrow networks of chip channels help perfectly mixing 
of materials together. The methods in use are divided into two 
categories: Active and Passive. Active types are Electro-kinetic, 
Acoustic and Magneto-hydrodynamic. Passive types include T- 
or Y-mixers, Lamination and Chaotic advection.
(Lee et al., 2011)
Table 3. Functions that Should be Included in a Diagnostic Microchip, as Well as Components and Common 
Techniques Used in Every Stage (Continued)
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which is promoted to 1 CTC per 105 mononuclear cells in 
metastatic phase. Conclusively, by using cancer associated 
biomarkers in blood and other body fluids the difficulties 
of traditional sampling have been obviated. This strategy 
is a fundamental step in screening and diagnosis of various 
types of cancer (den Toonder, 2011).
Single Cell Isolation
Nowadays, cell analysis techniques play important 
roles in designing the various drugs, tissue engineering, 
development of different cell lines, understanding the 
intracellular signaling, and stem cell & cancer research. 
This process is required efficient isolation and cultivation 
of the cells. One of the main challenges encounter with 
the cell isolation is the heterogeneous nature of target 
cells which highlights the needs for the development of 
single cell isolation and analysis techniques (Van Loo and 
Voet, 2014). With the respective of frequency, the most 
applicable technologies which currently used for single 
cell isolation purposes are flow cytometry (33%), manual 
cell picking (17%), laser micro-dissection (17%), random 
seeding/dilution (15%), and microchips (12%) (Gross et 
al., 2015). Among these, laser-directed micro-dissection 
is a strong method for the collection of malignant cells in 
solid tumors (Emmert-Buck et al., 1996). 
In some cases, the microchip technology is preferred 
for the cell isolation. For instance, when the cell analysis 
of a tumor bulk demands a high accuracy and sensitivity or 
in the cases where differentiation of viable and non-viable 
cells is required, using a microchip is almost inevitable 
(Zhao et al., 2013). The microchips which currently used 
specifically for single cell isolation generally work based 
on three main principles: Droplet-in-oil-based isolation 
(Brouzes et al., 2009), Hydrodynamic cell traps (Di Carlo 
et al., 2006), and Pneumatic membrane valving (Gomez-
Sjoberg et al., 2007). Sensitivity of basic method used in 
chip for single cell isolation, quality and yield of isolated 
cells, and the compatibility of isolation method with 
analysis hardware are among the top concerns regarding 
the use of microchips for cell isolation (Nagrath et al., 
2007). In the recent years, single cell isolation as a field 
of novel applied research has several subcategories. One 
of these subcategories is the isolation and purification 
of circulating tumor cells (CTCs) from blood as a non-
invasive sampling which is efficient for monitoring of 
cancer (Gross et al., 2015).
Isolation and Purification of CTCs using 
Microchip Technology
Obtaining useful information related to cancer 
pathogenesis and its monitoring requires isolation and 
purification of cancer cells from affected tissues, blood or 
other body fluids. Indeed, collection of circulatory tumor 
cells and conducting the complementary experiments 
on the samples using rapid and non-invasive methods 
provides a unique chance for clinicians to initiate 
the treatment procedures in early stages prior to fatal 
metastatic phase. CTCs are often accumulated in 
peripheral blood before full development of metastatic 
phase. It is clear that the detection and isolation of these 
cells can be performed more conveniently in this phase. In 
this stage, CTCs acquire secondary genetic abnormalities 
which are pre-requisite for a successful metastasis and 
formation of a new tumor originated from the primary 
tumor (Maheswaran and Haber, 2010). An ideal method 
for isolation of CTCs should be in consistent with the 
following criteria: high specificity and sensitivity, sample 
enrichment, and statistical consideration (Allan and 
Keeney, 2010). 
CTC isolation process is generally performed via 
various methods including: PCR-based approaches, 
Flow cytometry, Laser scanning cytometry, CellSearch 
(Veridex), EPISPOT, and microchip technology (Gross 
et al., 2015). Among these approaches, microchip 
technology along with EPISPOT and Veridex with the 
ability to detect one tumor cell among 107 peripheral 
blood mononuclear cells (PBMCs) is categorized as the 
most efficient and sensitive method for CTC isolation 
purposes. This technique is also the selective method 
where a large amount of pure cells is needed. Moreover, 
this technology is a powerful quantitative method which 
is able to differentiate the viable from non-viable cells 
and allows the distinct analysis of each group (Nagrath 
et al., 2007).
Undoubtedly, because of extremely low counts, CTCs 
demand highly sensitive methods to be isolated. To 
achieve this, one strategy is to use surface CD-markers 
to differentiate tumor cells from normal blood cells. For 
example, surface marker CD45 as a specific marker for 
non-tumor cells can be used to efficiently isolate the 
majority of tumor cells. However, using tumor specific 
CD-markers are associated with multiple challenges. 
One of these challenges is the variability of tumor cell 
immuno-phenotype during different phases of cancer 
(progression, metastatic, etc.) which makes the isolation of 
CTCs very complicated or in some cases, even impossible 
(Goodale et al., 2009). Furthermore, some tumor cells 
during the migration to the secondary tissue undergo a 
process so called epithelial-to-mesenchymal transition 
(EMT). During this process migration and metastasis 
potential of tumor is promoted, the cell-cell adhesion 
property is reduced, epithelial markers are decreased and 
mesenchymal markers are expressed, and even the cell 
morphology undergoes several alterations (Yang and 
Weinberg, 2008). As a result, discovering novel tumor 
specific biomarkers which are stable during different 
phases of cancer progression can propose the more 
sensitive strategies to isolate the CTCs. Stable tumor 
specific biomarkers are divided into two main categories: 
tumor type-specific markers, and epithelial-specific 
markers. In the first class, PSA, CEA, and Mammoglobin-
HER2neu-Mucin1 are the typical hallmarks for prostate, 
colorectal, and breast cancer, respectively (Xi et al., 2007). 
The most prominent tumor markers in the second class 
are EpCAM, also known as ESA, CD326, HEA125, or 
TACSTD1 and the various cytokines (Pantel et al., 2008).
One further challenge regarding the cancer monitoring 
is the isolation of CTCs in early-stage cancerous patients. 
In this case, prognostic markers which are expressed 
adequately in early stages should be considered as proper 
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target for detection (Allan and Keeney, 2010). The most 
applicable markers in this regard include cytokeratin-19, 
cytokeratin-20 or CEA, and PSA or PSCA which are used 
to isolate CTCs in early stages of breast, colorectal, and 
prostate cancers, respectively (Stathopoulou et al., 2003; 
Allen-Mersh et al., 2007; Helo et al., 2009). 
New approaches propose the expression measurement 
of genes encoding for biomarkers in the molecular 
levels. In this regard the following measurements can 
be mentioned: assessment of HER-2 gene amplification 
to determine the severity of breast cancer (Meng et al., 
2004), uPAR and HER-2 gene expression profile to 
monitor the breast cancer (Meng et al., 2006), insulin-
like growth factor-I receptor gene expression to ample 
purification of tumor cells (de Bono et al., 2007), detection 
of EGFR gene mutation to efficiently isolate the CTCs of 
lung cancer (Maheswaran et al., 2008), and EGFR gene 
expression profiling to isolate the CTCs of breast cancer 
after metastatic phase (Payne et al., 2009). 
One of the other challenges regarding the CTC isolation 
is associated with difficulties in sample enrichment. 
Enrichment approaches are generally based on one of two 
mechanisms of positive selection and negative selection. 
These mechanisms in turn use three main methods for 
Sample Enrichment: 1: immuno-magnetic methods, 2: 
density gradient centrifugation, and 3: cell size restrictive 
filtration (Allan and Keeney, 2010). Taken together, using 
microchips due to high efficiency, acceptable precision 
and sensitivity, and affordable prices is one of the most 
ideal methods for effective isolation of CTCs from blood. 
In the following sections multiple CTC isolation methods 
using microchips are described. 
Microchip Mediated CTC Isolation Using 
Size-Based Technology
Microchips designed based on this technology 
differentiate the CTCs from normal blood cells regarding 
their different sizes (Kim et al., 2015). As an advantage, 
in this method the needs for specific biomarkers are 
obviated, while tumor cell size heterogeneity is considered 
a challenging feature which can fail the purification of 
small size tumor cells. However, in this technology using 
8-11μm diameter micro-cavities or 5-7μm wide slots 
allows the efficient isolation of tumor cells of various 
sizes (Hosokawa et al., 2010).
Alternatively, in some cases the flow profile of cells 
which is based on inertial migration is applied to separate 
the tumor cells with huge sizes (Bhagat et al., 2011). In 
this regard, dielectrophoretic force with a higher accuracy 
and sensitivity may also used to isolate the cells (Moon 
et al., 2011). One of the primary studies in this case has 
been made in 2000 in which Dielectrophoretic Field-Flow 
Fractionation (DEP-FFF) was used to selectively isolate 
the different types of blood cells (Yang et al., 2000).
In 2007 and 2011 Zheng et al. have succeeded to isolate 
the CTCs using a microchip with specialized micro-filter 
membrane which is able to sensitively discriminate the 
tumor cells based on their different sizes (Zheng et al., 
2007; Zheng et al., 2011). Similarly, in another study 
particular chips so called “filtration chips” with a spiral 
channel and two filters were used for purification of breast 
cancer cells from the blood with remarkable efficiency 
(Kuo et al., 2010). In 2011, tumor cells were isolated 
with an excellent efficiency (96% yields) from diluted 
blood. In this study the special chips were used in which 
cell morphology was also added to the isolation criteria 
further than the cell size. These microchips take advantage 
of a distinct technology referred to as “deformability-
based analysis” (Hur et al., 2011). Another favorable 
result was taken in the same year using dielectrophoretic 
features as an alternative strategy to isolate the CTCs 
from blood samples (Moon et al., 2011). In 2012, Lim EJ 
et al have been elected to use a method called “particle 
trajectory analysis” in order to isolate the prostate cancer 
cells. Microchips using this technology are categorized 
as “particle focusing chips” which use the cell size 
characteristics for the isolation purposes (Seigneuric et 
al., 2010).
Microchip Mediated CTC Isolation Using 
Immunoaffinity-Based Technology
In this technology, the isolation is conducted using 
one of the tumor specific markers. The antibodies play 
an integral role in Immunoaffinity-based CTC isolation 
methods. They specifically identify the target tumor 
markers that eventually form an Ag-Ab complex which 
can be targeted to isolate the CTCs in the sample (Zhang 
and Nagrath, 2013). 
In 1970s a surface antigen called Epithelial Cell 
Adhesion Molecule (EpCAM) was identified to be 
highly expressed on the surface of the cells in several 
tumors including colon, prostate, lung, kidney, breast, 
and ovarian cancers. In 2004, EpCAM was selected as 
a proper target for monoclonal antibodies in order to 
isolate the CTCs in blood samples using Veridex which 
is a macro-scale method (Zhang and Nagrath, 2013). 
This antigen is a biomarker which is also extensively 
used as a target for CTC isolation in micro-scale methods 
such as Immunoaffinity-based chip technology (Nagrath 
et al., 2007). As a disadvantage, this method is not a 
proper choice where the viable cells are needed. In these 
cases sized-based or dielectrophoretic-based methods 
are preferable. This limitation is strongly attributed to 
vulnerability of the viable cells to some steps of the 
procedure such as washing of antibodies which are bound 
to surface antigens with a high affinity. In addition, the 
target cells might also be contaminated with unwanted 
cells due to the unspecific binding of the antibodies 
(Zhang and Nagrath, 2013). Obviously, the slight amount 
of tumor cells through a multitude of normal blood cells 
augments the complexity of problem which leads to 
unreliable analysis. 
In 2009, a new approach of CTC isolation was 
developed as “aptamer selection chip” which possesses 
a strong ability of isolation based on immunoaffinity 
technology (Dharmasiri et al., 2009). In the following year, 
“Herringbone-chips” which are PDMS in texture were 
described with a high ability to isolate CTCs of prostate 
cancer in blood samples (Stott et al., 2010). Subsequently, 
geometrically enhanced differential immunocapture 
Asian Pacific Journal of Cancer Prevention, Vol 17, 2016 887
DOI:http://dx.doi.org/10.7314/APJCP.2016.17.3.879
Microchips and their Significance in Isolation of Circulating Tumor Cells and Monitoring of Cancers
(GEDI) chips were used to collect the CTCs of this type 
of cancer (Gleghorn et al., 2010). In another study in 2010, 
simultaneous use of E-selectin and EpCAM antigens 
was discussed to have a higher specificity for isolation of 
CTCs. The mechanism behind was the fact that combined 
use of the two antigens enhances the marginalization of 
CTCs on blood vessels, a process which facilitates the 
CTC isolation. This micro-fluidic system is referred to 
as “E-selectin biomimetic chip” (Myung et al., 2010). A 
study in 2011, in order to detect the KRAS gene mutation 
in colorectal cancer, used a special sort of chips named 
“Integrated CTC selection chips” with a remarkable 
capacity for tumor cell isolation (Dharmasiri et al., 
2011). Later in 2013, NCI-1650 antigen was applied as 
an immunologic target with a nitrocellulose membrane 
as scaffold to isolate the CTCs of lung cancer (Zhang et 
al., 2013). In the same year Zhao et al. designed a system 
called “NanoVelcro Chip” coupled with ArcturusXT™ 
laser capture microdissection (LCM) technology to 
isolate the CTCs of prostate cancer for the next generation 
sequencing [NGS] purposes (Zhao et al., 2013). In 2014, 
a modern microchip named “geometrically enhanced 
mixing (GEM) chip” was successfully used to isolate 
the pancreatic cancer CTCs with a great specificity and 
accuracy (Sheng et al., 2014). At the same time a new 
generation of microchips adopted simultaneous use of 
EpCAM and Caveolin-1 antigens to isolate the CTCs 
through a heterogeneous population of cells in breast 
cancer patients (Kim et al., 2014).
Microchip Mediated CTC Isolation using 
Immunomagnetic-Based Technology
The only FDA approved method for tumor cell or stem 
cell purification from fluids such as blood is a macro-
scale technology (Veridex) which uses immunomagnetic 
labeling to capture the target cells. Currently, new 
generation of chips in micro-scales have been developed 
which are able to collect the magnetically-labeled CTCs 
from blood samples (Chen et al., 2011b). In 2009, a sort 
of chip called “Magsweeper chip” with immunomagnetic 
separation technology was applied to isolate the breast 
cancer cells from whole blood (Moon et al., 2011). 
In 2010, a different type of this category called “self-
assembled magnetic chip” introduced for high efficient 
isolation of B lymphocytes from blood samples of 
leukemia and lymphoma patients (Saliba et al., 2010). 
Along with these studies, in 2011 a special group of 
chips referred to as “negative selection chips” were used 
to isolate breast cancer cells from PBMCs, however this 
group was associated with a moderate efficiency (60% 
yields) (Chen et al., 2011a). The combined micro-magnetic 
micro-fluidic device as a novel chip system was developed 
in 2012 to purify the tumor cells but the efficiency did not 
overtake the former method (Kang et al., 2012).
Detailed Investigation of Cancer Biology 
Using Microchip Technology
In the recent years a body of various methods 
has been applied for diagnosis, monitoring, as well 
as studying the underlying mechanisms of cancer. 
All the previously described approaches have their 
own advantages and disadvantages. They have also 
associated with heterogeneous degrees of accuracy and 
sensitivity. In a quick glance, currently available cancer 
diagnosis and monitoring techniques include pathologic 
examination, various PCR analysis, blotting techniques, 
DNA microarray, tissue microarray, flow cytometry 
and immunophenotyping, immuno-histochemistry, 
cytogenetic studies, FISH, and genome sequencing. 
Among this diverse range of approaches, DNA microarray 
is one of the most applicable and efficient strategies for 
extensive screening of tumors. This technology is also 
known as Gene array, Chips, and Biochips and should 
not be confused with tissue microarray (Aitman, 2001). 
This system generally exerts its role in understanding of 
the biology behind the diseases in the frame of three main 
forms: gene expression profiling, DNA sequencing, and 
genotyping (Fey, 2002). 
A comprehensive bulk of information on biology and 
pathogenesis of different types of human cancers can be 
deciphered using DNA and RNA molecules of tumor 
cells extracted from blood and other clinical samples 
including saliva, urine, sputum, stool, and bronchial 
lavage materials (Zhang and Nagrath, 2013). Moreover, 
using large spectrum of other macromolecules such as 
various ranges of proteins, hormones, lipid molecules, 
micro-RNAs, as well as serum micro-vesicles contributes 
to a better understanding of basic mechanisms of diseases 
and finding the novel diagnostic and treatment strategies 
(Zhang and Nagrath, 2013).
miRNAs constitute approximately 1% of human 
genes and they are encoded as mono- and poly-cistronic 
genes. The genes encoding these small non-coding 
RNAs are located either independently or between 
other protein-coding regions. The most segments of the 
genome responsible for miRNA coding are not dedicated 
for other specific genes. MiRNA specific arias include 
fragile regions on human chromosomes and expressed 
independently of the others genes. RNA polymerases I 
and II transcribe the miRNA genes into primary miRNA 
transcripts. MiRNAs have been discovered to be largely 
involved in several metabolic and pathologic processes 
including tissue formation, cell proliferation and death, 
lipid metabolism, stem cell differentiation, as well as 
cancer formation and progression. Regarding these 
diverse functions, the roles of miRNAs in vertebrates are 
comparable with transcription factors (Wang et al., 2016). 
Furthermore, circulatory miRNAs are stable elements 
which currently are considered as highly valuable 
biomarkers for diagnosis and monitoring of human cancers 
(Tsujiura et al., 2010).
Additional potential biomarkers used for cancer 
diagnosis and monitoring are micro-vesicles or exosomes. 
However, exosome-based cancer diagnostics requires 
techniques enabling the differential identification of 
exosomes from extremely similar elements in blood 
samples (Ratajczak et al., 2006). Exosomes are protective 
structures encircling a group of proteins, lipids, and 
miRNAs. The resulting structures have a size of 60-
100nm, which exist both as intracellular and circulating 
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Table 4. A List of the Most Important Exploitations and Studies in the Field of the Biology, Diagnosis, Treatment, 
and Monitoring of the Cancer Using Microchip Technology
Reference Results Study description
Techniques used in 
the frame of chip 
technology
(Wang et al., 2015b)
No false positive result in negative control 
group or false negative result in patient 
group was detected. It was even detected 
a JAK2 positive patient which was missed 
before by other methods. 
Chip-based screening of Jak2 
V617F point mutation for 
diagnosis of lymphoproliferative 
disorders especially polycytemia 
vera. 
DNA extraction 
& amplification & 
mutation analysis
(Ying-Yan et al., 
2008)
GRP78 is a chaperone responsible for 
chemotherapy resistance is some cancer 
types. GRP78 in A23187 induced cells was 
over-expressed and after VP-16 exposure the 
apoptosis rate significantly diminished. It 
was concluded that GRP78 plays an integral 
role In cell lines resistance to chemotherapy.
NCI-H460 cell line representing 
the lung cancer was cultured on 
PMDS microchips in the presence 
and absence of A23187. Then the 
GRP78 expression was measured 
in both mRNA and protein levels. 
Ultimately, cell apoptosis assay 
was performed after VP-16 (a 
chemotherapy drug) exposure. 
Cell culture, 
Immunofluorescence 
& Electrophoresis
(Munro et al., 1999)
Time required for testing in slab-gel 
was about two and a half hours and in 
conventional CE microchip about 15 
minutes. This time with greater efficiency, 
reduced to less than three minutes in chip 
systems.
Optimization of molecular 
diagnosis of B, and T 
lymphoproliferative disorders 
in slab gel electrophoresis, 
conventional CE, and micro-
fluidic systems.
Electrophoresis
(Tian et al., 2000a)
By using chip, the time required to perform 
single-strand conformation polymorphism 
analysis and the type and structure 
optimization fell to about two minutes and 
the efficiency promoted to more than a 
hundred-fold.
Detection optimization of the 
genomic aberrations such as 
mutations, deletion etc. in the 
genes including BRCA1 and 
BRCA2 using hetero-duplex 
analysis and allele-specific 
DNA amplification techniques 
or a combination of these two 
techniques in CE chips.
combining allele-
specific DNA 
amplification 
with heteroduplex 
analysis by capillary 
electrophoresis chip
(Schrauder et al., 
2012)
46 miRNAs were detected to be down-
regulated and 13 miRNAs had significant 
increase in expression levels. MiR-202, due 
to its remarkable decrease was considered as 
a significant preventive element of the breast 
cancer formation.
MiRNAs profiling in early stages 
of breast cancer patients on 
especial chips.
Array-based miRNA 
profiling
(Sato et al., 2001)
Using chips in this study resulted in the 
reduction of CEA detection time from 45 
hours to 35 minutes. Additionally, the sensi-
tivity and reproducibility of the method was 
significantly increased compared to macro-
scales techniques.
Tracing of carcino-embryonic 
antigen in human saliva using 
three different antibodies based 
on chip technology for diagnosis 
of colon cancer.
Sandwich 
immuoassay
(Chaw et al., 2007)
Cancer cells, intelligently migrated toward 
the center of channels with complete culture 
medium. In this study, the cell membrane 
was introduced as a therapeutic target in 
controlling the cancer metastasis. 
Study of metastatic and 
deformation pattern of cancer 
cells using cell culture on the 
margins of microchip channels in 
the serum deficient medium.
co-culture for 
studying cancer 
metastasis
(Cantafora et al., 
2003)
Cholesterol was proposed as a positive 
inductor of the factors such as LXR-alpha 
and FXR.
Study of RNA messengers that 
involved in lipid trafficking 
of human intestinal cells. The 
technology used in this study 
include: RT-PCR with competimer 
technology and microchip CE
reverse-transcription 
polymerase chain 
reaction
in blood (Taylor and Gercel-Taylor, 2005).
Nowadays, highly advanced micro-fluidic systems 
have been introduced to detect all the above mentioned 
biomarkers in blood samples and other body fluids. These 
micro-scale systems have increasingly attracted many 
cancer investigation and clinical centers to use them as 
proper alternative methods rather than high price macro-
scale strategies (Hung et al., 2013). Using slight amounts 
of samples with remarkably sensitive, accurate, high 
throughput, and reproducible results allows microchips to 
be extensively used for tumor diagnosis and monitoring 
(Pappalardo et al., 1998). 
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(Yung et al., 2009)
EGFR related to exon-19 deletion and 
L858R mutation were reported in 17% and 
26% plasma samples, respectively. Plasma 
concentrations of mutant sequences were 
shown to have a significant reduction in 
patients with remission.
Detection of two common types 
of EGFR (in-frame deletion in 
exon-19 and L858R at exon-21) 
in plasma and tissue samples 
of patients with lung cancer 
using micro-fluidic systems and 
quantitative confirmation of these 
two disorders in patient’s samples. 
Digital PCR platform
(Song et al., 2009)
The pattern of implantation of tumor cells is 
fully targeted and is associated with the organ 
microenvironment. Microenvironment of 
organs was considered as therapeutic targets 
in cancer control.
The effects of simulated vascular 
system and chemokines CXCL-
12 on development and grading 
determination of cancer cells on a 
microchip.
co-culture for 
studying tumor 
microenvironment
(Mitchell et al., 
2008)
MiR-141 in these patients was significantly 
overexpressed and could be considered as an 
important biomarker. 
Application of microchips to 
determine the profile of micro-
RNAs in prostate cancer (serum 
samples).
TaqMan miRNA 
qRTPCR array
(Huang et al., 2009)
A week after the co-culture, the macrophages 
have invaded against the breast cancer 
cells. Profiling of stromal cells in the 
microenvironment of metastatic cancers 
can be used as therapeutic targets in cancer 
control.
The effects of stromal cells on 
biology of metastatic breast 
cancer cells during co-culture 
of these cells together on the 
hydrogels designed in chips.
3D-culture for 
studying interactions 
between tumor and 
stromal cells
(Pekin et al., 2011)
6 new mutations in the KRAS genes 
have been reported. In this study, the 
determination of exact quantity of mutant 
alleles was also possible. Its sensitivity is so 
high that one single mutant KRAS gene is 
able to be detected among 200,000 normal 
alleles.
Detection of rare mutations of 
KRAS gene in several cancer cell 
lines on a single chip
Droplet-based quanti-
tative PCR
(Mousa et al., 2009)
Estrogen levels in breast cancer patients 
significantly increased in some stages and 
can be considered as an indicator of disease 
progression.
Microchip-based determination 
of the estrogen levels in the blood 
and tissue samples of patients 
with cancer.
droplet-based estro-
gen detection assay
(Sung et al., 2011)
In the presence of fibroblasts, tumor 
cells become more aggressive. Therefore 
fibroblasts inhibitor drug have the potential 
to prevent the cancer progression.
Culture of cancer cell line MCF-
DCIS with fibroblasts in adjacent 
laminars on a chip to determine 
the significance of fibroblasts in 
cancer biology and development.
co-culture for study-
ing tumor progres-
sion
(Kim et al., 2012)
This system provides the possibility of 
designing an efficient drug screening system 
which contributes to control various cancers. 
The effect of different concen-
trations of sensitizer and death 
inducer drugs on prostate cancer 
cells in a 64-well chip made of 
PDMS.
Cell culture microar-
ray
(Chen et al., 2010)
It was shown that there are various mRNAs 
and miRNAs inside the micro-vesicles with a 
little diversity in ribosomal RNA. Moreover, 
it was deciphered that the micro-vesicle 
levels in normal saliva are significantly 
lower than patient saliva samples. It was 
also indicated that mRNA levels of GAPDH 
and IDH1 in both patients and normal group 
is remarkably greater where the anti-CD63 
coated surfaces were used.  
Isolation of micro-vesicles 
from saliva of patients with 
glioblastoma multiform using 
anti-CD63 coated surfaces, RNA 
extraction from vesicles and 
detection of point mutations; on a 
multifunctional microchip. 
Exosome isolation 
and RT-PCR analysis
Table 4. A List of the Most Important Exploitations and Studies in the Field of the Biology, Diagnosis, Treatment, 
and Monitoring of the Cancer Using Microchip Technology (Continued)
Regarding the history of using microchips for 
cancer study purposes the following studies are among 
the pioneering efforts in this promising path: cDNA 
microarray for gene expression profiling of human cancers 
(1996) (DeRisi et al., 1996), molecular analysis of tumor 
cells using microchip technology (1998) (Pappalardo et 
al., 1998), chip-based gene expression profile of human 
melanoma cells (1999) (Huang et al., 1999), designing 
of chips for molecular diagnosis of lympho-proliferative 
disorders (Munro et al., 1999), designing a especial 
Lymphochip for gene expression profiling of different 
types of diffuse large B-cell lymphomas (DLBCL) 
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(White et al., 2011)
Heterogeneous expression was detected for 
miR-223, miR-196a, and miR-145 in K562 
cell population. While miR-92 and miR-17-
5p showed a uniform pattern of expression 
in all the cells. In aim2, miR-145 showed 
20 fold increases in expression and OCT4 
was down-regulated by 30 fold. Prevalence 
of SP1 mutant allel for homozygote and 
heterozygote forms was shown to comprise 
1% and 19% of cell population, respectively. 
MiRNA expression profiling in 
K562 cell line (aim1); expression 
analysis of miR-145 and its main 
targets during embryonic stem 
cell differentiation (aim2); The 
prevalence of mutant allel and 
single nucleotide polymorphisms 
(SNPs) of transcription factor SP1 
in metastatic breast cancer cells 
(aim3) on a single microchip. 
Single-cell miRNA 
expression analysis 
By RT-quantitative 
PCR
(Nasedkina et al., 
2014)
Prevalent mutations were reported in 8% of 
patients. BRCA1-5382incC and CHEK2-
1100delC mutations were detected in 
3.9% and 1.7% of breast cancer patients, 
respectively. 
Using microchips for mutation 
analysis of BRCA1, BRCA2, and 
CHEK2 genes patients with breast 
cancer in Russia. 
Genotyping by Mi-
croarrays
(Wang et al., 2015c)
At first, HE4 protein is absorbed to its special 
destiny in chip, and after the primary and 
secondary antibodies the specific substrate 
is added. Finally, the color producing 
reaction is occurred and the intensity of 
color can be calculated by specific devices 
or even cell phones. By using this chip HE4 
concentration in urine is determined thus the 
early diagnosis of ovarian cancer becomes 
possible.
Detection of HE4 biomarker 
using a specialized microchip in 
urine samples of ovarian cancer 
patients. 
ELISA-based chips
(Zubcova Zh et al., 
2013)
Several tumor markers were reported to be 
up-regulated in 77% of patient’s sera and 
6% of normal sera. Simultaneous analysis of 
multiple tumor markers represents a better 
screening than single biomarker detection.
Chip based simultaneous 
detection of multiple tumor 
markers including AFP, CEA, 
HCG, CA 15-3, CA125, CA19-
9, PSA, and NSE for efficient 
screening of breast cancer.
Immunoassay
(Leng et al., 2014)
Using PCR-Capillary Electrophoresis and 
microchip, respectively 32% and 27% of 
AML samples were reported as positive 
for FLT3-ITD mutation. Statistical analysis 
showed a desired precision and sensitivity 
for the both methods. 
Comparison of two methods 
(chip- and PCR capillary 
electrophoresis-based) for AML 
screening based on detection of 
FLT3-ITD gene mutation.
PCR-Microchip 
Electrophoresis
(Lin et al., 2013)
In this study, using a combination of two 
techniques on a single chip allowed the 
high sensitive simultaneous detection of 
two separate transcripts of the fusion gene 
including b2a2 and b3a2.
Design of specialized chip 
technique to analyze the BCR-
ABL gene fusion for clinical 
diagnosis of CML.
RT-PCR & 
Electrophoresis
(Pilarski et al., 
2005)
This strategy requires the minimum amounts 
of starting sample (5% of that used in ABI-
3100 system). This tiny consumption also 
associates with a remarkable precision 
compared with macro-scale models, which 
can facilitate the diagnosis of multiple 
myeloma patients. 
Using microchips for precise 
identification of IgH-VDJ 
recombinant transcripts in 
multiple myeloma-derived 
plasmacells. 
Detection of singe 
cell PCR products 
by Capillary 
Electrophoresis
(Ziober et al., 2008)
Simultaneous analysis of a panel of 25 genes 
responsible for oral cancer was performed 
using microchip on patient’s saliva samples. 
The diagnosis and screening were conducted 
on the samples with greater rate of precision, 
sensitivity, and reproducibility compared 
with previous methods.  
Microchip-based screening and 
diagnosis of oral cancer on the 
saliva samples. 
multiplex RT-PCR
Table 4. A List of the Most Important Exploitations and Studies in the Field of the Biology, Diagnosis, Treatment, 
and Monitoring of the Cancer Using Microchip Technology (Continued)
and molecular-based classification of these disorders 
(Alizadeh et al., 2000), using an electrophoretic-based chip 
for rapid and accurate detecting of mutations in BRCA1/2 
genes in breast cancer (2000) (Tian et al., 2000), and the 
tracing of carcino-embryonic antigen in human saliva 
samples for the diagnosis of colorectal cancer (2001) (Sato 
et al., 2001). In this regard, many targeted research studies 
have been carried out to date with successful results as 
summarized in Table 4.
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Conclusions and Future Perspectives
According to the above mentioned concepts, using 
the circulating tumor cells (as the test sample) and small, 
cheap, reliable and portable microchips (as the test 
environment), the human being has taken a laudable step 
toward a more accurate monitoring of cancer. However 
in this path several challenges exist which are yet to be 
fully addressed.
One of the top limitations regarding the use of 
these micro-fluidic systems for cancer monitoring is 
their incapability to isolate the tiny amounts of CTCs 
from blood samples of patients with early stages of 
malignancies before the metastatic progression ( it is ideal 
to isolate 5 tumor cells among 100 million blood cells). 
Undoubtedly, if the malignancy would be detectable in 
such early stages the chance for patients remission and 
survival reaches to its maximum state (Bunger et al., 
2015). Prospectively, this problem also will able to be 
resolved using specialized and more efficient chip design 
as well as advanced materials. In this regard, effective 
strategies to increase the sensitivity of microchips have 
been also proposed (Chiu et al., 2015).
Identification of highly specific biomarkers with 
stable expression through which the tumor cells would be 
detectable in every stage of the disease can be a proper 
strategy to make these systems more efficient (Lianidou 
et al., 2015). Using novel biomarkers for CTC isolation 
as well as gene expression profiling can also help to 
pave the way toward a more desirable cancer monitoring 
(Lianidou et al., 2015). Another solution is to identify new 
prognostic biomarkers that are certainly best harbingers 
of the early stages of cancer, a principle which can be 
applied to prevent the metastasis formation. CA19, CA20 
and PSCA are among these biomarkers (Muluneh and 
Issadore, 2014). Recently the creation of nanowires is 
considered a great success as a strategy which is capable 
of high throughput CTC isolation. These systems are 
specialized microchips for detection of small amounts of 
circulating tumor cells. These microchips contain several 
nanowires coated with monoclonal antibodies against 
specific biomarkers (Wang et al., 2015). Nanowires have 
been able to impressively increase the sensitivity of CTC 
isolation and herald a bright future in the early stage 
diagnosis of cancer (Wang et al., 2015).
As a real concern, nowadays what that many modern 
research laboratories take under study are still far from 
those which are required in practice and clinical trials. 
This means that the abundance of research data cannot be 
easily translated into clinic (Bean, 2001). This challenge 
has been slightly obviated by using microchips. Indeed, 
the simulation of in vivo environment into micro-fluidic 
systems is a cheaper, easier and faster than macro-scale 
models. Moreover, the results obtained from these 
systems can be easily attributed to real physiology of 
in vivo environment with high accuracy and sensitivity. 
In fact, using microchips and their ability to investigate 
the detailed layers of cellular and molecular interactions 
have been able to largely destroy the barrier between the 
research laboratory data and clinical practices (Bean, 
2001).
As another main challenge regarding the microchips is 
that they extensively applied in the research levels while 
they are slightly used in routine clinical diagnosis. Using 
(Alley et al., 2010)
After analyzing the results, a biantennary-
mono sialylated N-linked glycan and a 
triantennary-trisialylated element were 
proposed as two useful biomarkers for 
detection of aggressive breast cancers.
The introduction of a precise 
micro- system to find the N-linked 
glycan biomarkers in order to 
better diagnosis of breast cancer. 
Reversed-
phase Liquid 
Chromatography-
Mass Spectrometry
(Hestekin et al., 
2011)
In less than ten minutes, the detection of 
P53 gene mutation was performed with 
the sensitivity of 98% and specificity of 
100%. In this method, both DNA strands are 
labeled, which leads to a clear increase in its 
specificity. The chip which was designed for 
this study, allowed the detection of all the 
possible mutations in P53 gene exons.
Designing a sensitive and accurate 
method to evaluate a variety of 
P53 gene mutations on one chip
electrophoresis–
SSCP/HA
(Raamanathan et al., 
2012)
The accuracy of the results in this study is 
comparable with ELISA. This method is low 
cost; it can be done in a short time; is able to 
detect ovarian cancer in its early stages with 
a high reproducibility. It is also suitable for 
Point-of-care testing.
Serum quantification of CA125 
for the diagnosis and monitoring 
of ovarian cancer in the form of 
a programmable bio-nano-chip 
(p-BNC).
fluorescence-
based sandwich 
immunoassay
(Shi et al., 2012)
In this study, membrane and cytoplasmic 
protein dosage as well as the profiling of 
protein-protein interactions in the tumor 
cells was determined. The system creates 
a snapshot of the tumor cell signaling, and 
understanding of cancer biology and drug 
design to treat them more convenient than 
the past.
Using microfluid to study the 
signaling pathways in a group of 
tumor cells
Single-cell 
proteomics
Table 4. A List of the Most Important Exploitations and Studies in the Field of the Biology, Diagnosis, Treatment, 
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microchip as a versatile technique and its accessibility 
to all the personnel and specialists requires a huge 
investment and a consistent administrative policy. 
Undoubtedly, achieving this goal will be a big turn in 
routine diagnostic of various disorders especially for 
cancers (Kuo and Chiu, 2011). On the other hand along 
with the specialized micro-fluids used for detailed scrutiny 
of disorders, the design of micro-systems for point-of-care 
diagnosis allows the monitoring of malignancies much 
faster than the traditional methods (Ng and Wheeler, 
2015). A modern derivative of chip systems which has 
facilitated the understanding of cancer biology is referred 
to as “Risk-on-a-chip” system. Recently this method has 
been utilized to predict the time when the breast cancer 
progressed toward a high-risk stage (Vidi et al., 2013). In 
this regard designing more specialized microchip systems 
for a broad range of human cancers would pave the way 
toward a great success in controlling of cancers before 
entering into their invasive stages. 
Currently, exosomes have been proposed by many 
scientists as novel biomarkers for early detection of cancer 
formation (Li et al., 2015). Macro-scale models for the 
purification and analysis of exosomes are labor intensive, 
time consuming, and expensive. They are also associated 
with a low accuracy and sensitivity and very difficult 
to be optimized. Furthermore, macro-scale systems 
demand large amount of samples, a requirement that is 
almost impossible about exosomes. The new generations 
of micro-systems have been successful to obviate these 
predicaments as they are able to analyze the exosomes in 
minute concentrations. These microchips have gained a 
huge volume of useful information about the mechanisms 
behind the biology of cancers; however this field is 
encountered with a great spectrum of ambiguities which 
requires more clarifications (Kanwar et al., 2014).
In a quick glance, several characteristics of a microchip 
can under shadow its overall functions which are include: 
the physics of the chip and its dimensions; material used 
in its synthesis; types of pumps, channels and valves; chip 
manufacturing technology; the type, quantity, quality and 
sample processing, reliability, standardization, precision 
and the sensitivity of chip for sampling, analysis and 
final recording of the results. In the near future each of 
these features might be a topic for different challenges 
and investigations. Conclusively, further development 
of ingeniously designed micro-systems, identification 
of proper materials with a high bio-compatibility for 
chip manufacturing, discovering novel biomarkers, 
optimizing the integration of various processes on a 
single platform, and using highly efficient bio-detectors 
in the structure of microchips can help to largely enhance 
the early diagnosis of human cancers. In fact, in the 
current scientific community which with the advent of 
modern technology and advanced equipments is rapidly 
developing, chip-based cancer monitoring like the other 
large research projects has been turned out to an extensive 
field of study and has been able to obviate many concerns 
regarding the human cancers and the related challenges. 
It is valuable to note that this trend is progressively going 
through forward which can bring promising achievements 
for health-care system. 
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